Skip to main content
Premium Trial:

Request an Annual Quote

ALSA Renews Funding for Biomarker Project

NEW YORK, Nov. 3 (GenomeWeb News) - A consortium including researchers from Metabolon has received funding to continue research to find biomarkers that indicate the presence of amyotrophic lateral sclerosis, the ALS Association said yesterday.


The organization did not release actual figures for individual projects, said Mark Yard, from ALSA's research depeartment.


The award will last one year, beginning Nov. 1 and ending Oct. 31, said Metabolon's Stephanie Ferrell.


The ongoing project has already produced a candidate panel of molecules in body fluids that differ between people with the disease and controls. Researchers identified a set of 19 proteins.


Researchers will continue testing samples with a focus on cerebrospinal fluid, since the highest level of biomarkers may occur there, and seek proteins and metabolic biomarkers that are specific to ALS. 


Metabolon previously received funding from ALSA in February 2004 to find biomarkers that indicate the presence of ALS, also called Lou Gehrig's disease. Metabolon has also received grants from NIH's National Institute of Environmental Health Sciences and from National Institute of Neurological Disorders and Stroke since the beginning of 2004.


The consortium includes researchers from Massachusetts General Hospital, Metabolon, Duke University, and University of Pittsburgh.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.